Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of RVT-1401 in Warm Autoimmune Hemolytic Anemia
2019-003924-19Phase 2Terminated
- Sponsor
- Immunovant, Inc.
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of batoclimab in warm autoimmune hemolytic anemia (wAIHA), sponsored by Immunovant, Inc. Primary endpoint: Proportion of responders at week 13. Started Jan 2020; status: terminated.
02
Drugs
batoclimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on 2019-003924-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003924-19.